MX2012002366A - Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. - Google Patents

Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.

Info

Publication number
MX2012002366A
MX2012002366A MX2012002366A MX2012002366A MX2012002366A MX 2012002366 A MX2012002366 A MX 2012002366A MX 2012002366 A MX2012002366 A MX 2012002366A MX 2012002366 A MX2012002366 A MX 2012002366A MX 2012002366 A MX2012002366 A MX 2012002366A
Authority
MX
Mexico
Prior art keywords
receptor agonists
adrenergic receptor
derived beta
novel pyrrolidine
pyrrolidine derived
Prior art date
Application number
MX2012002366A
Other languages
English (en)
Inventor
Philip Jones
Neville J Anthony
Christopher F Thompson
Gregori J Morriello
Cheng Zhu
Scott D Edmondson
Nam Fung Kar
Dong-Ming Shen
Lehua Chang
Christopher J Moyes
Graham F Smith
Mark E Scott
Joon Jung
Carolyn Cammarano
Dawn Marie Hoffman
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2012002366A publication Critical patent/MX2012002366A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención provee compuestos de fórmula (I): (ver fórmula (I)) composiciones farmacéuticas de los mismos, y método de uso de los mismos, en el tratamiento o prevención de enfermedades mediadas por la activación deI adrenoceptor ß3.
MX2012002366A 2009-08-27 2010-08-24 Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina. MX2012002366A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23748709P 2009-08-27 2009-08-27
PCT/US2010/046468 WO2011025774A1 (en) 2009-08-27 2010-08-24 Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Publications (1)

Publication Number Publication Date
MX2012002366A true MX2012002366A (es) 2012-03-29

Family

ID=43628346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002366A MX2012002366A (es) 2009-08-27 2010-08-24 Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.

Country Status (10)

Country Link
US (1) US8604038B2 (es)
EP (1) EP2470012B1 (es)
JP (1) JP5671538B2 (es)
CN (1) CN102573471B (es)
AU (1) AU2010286694B2 (es)
BR (1) BR112012004333A2 (es)
CA (1) CA2770475C (es)
IN (1) IN2012DN00971A (es)
MX (1) MX2012002366A (es)
WO (1) WO2011025774A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103140134B (zh) * 2010-07-23 2015-07-29 默沙东公司 新吡咯烷衍生的β3肾上腺素能受体激动剂
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3052099B1 (en) 2013-10-03 2019-08-21 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
JP2018519292A (ja) * 2015-07-01 2018-07-19 ファーマケア，インク． リシルオキシダーゼ様２阻害剤およびその使用
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
IL258856B1 (en) 2015-10-23 2024-03-01 Velicept Therapeutics Inc Zwitterion solvegron and its uses
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10408983B2 (en) 2016-08-16 2019-09-10 Moxtek, Inc. Durable, high performance wire grid polarizer having permeable junction between top protection layer
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2020123847A1 (en) * 2018-12-12 2020-06-18 Rutgers, The State University Of New Jersey Organic compounds
GB202113588D0 (en) 2021-09-23 2021-11-10 Atrogi Ab New compounds and methods
CN113816917B (zh) * 2021-11-19 2022-02-18 奥锐特药业(天津)有限公司 一种维贝格龙中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO822514L (no) * 1981-07-22 1983-01-24 Syntex Inc Fremgangsmaate ved fremstilling av terapeutisk virksomme 2,5-substituerte pyrrolidinderivater
US6015824A (en) * 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
AU2009231967B2 (en) * 2008-04-04 2013-02-07 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
EP2470021B1 (en) * 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists

Also Published As

Publication number Publication date
US8604038B2 (en) 2013-12-10
CA2770475A1 (en) 2011-03-03
EP2470012B1 (en) 2014-11-05
JP5671538B2 (ja) 2015-02-18
US20120225886A1 (en) 2012-09-06
AU2010286694A1 (en) 2012-03-08
AU2010286694B2 (en) 2013-09-12
JP2013503167A (ja) 2013-01-31
CN102573471A (zh) 2012-07-11
IN2012DN00971A (es) 2015-04-10
CN102573471B (zh) 2014-11-26
CA2770475C (en) 2017-06-27
EP2470012A1 (en) 2012-07-04
BR112012004333A2 (pt) 2015-09-08
EP2470012A4 (en) 2013-01-09
WO2011025774A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
MX2012002366A (es) Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
NI201000164A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
UA115136C2 (uk) Заміщені 4-фенілпіридини для лікування хвороб, пов'язаних з рецептором nk-1
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
TW201713640A (en) Bruton's tyrosine kinase inhibitors
IN2012DN02735A (es)
IN2012DN02730A (es)
IN2012DN00754A (es)
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
TN2012000002A1 (en) Gpr119 agonists
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2011014029A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
MX2012004780A (es) Inhibidores de akt.
TW200738659A (en) Novel compounds
JO2645B1 (en) Vehicles
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
GB0611907D0 (en) Compounds
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERCK SHARP & DOHME CORP.*

HC Change of company name or juridical status

Owner name: MERCK SHARP & DOHME CORP.*

FG Grant or registration